RESEARCH ARTICLE

Major depressive symptoms in breast cancer patients with ovarian function suppression: a cross-sectional study comparing ovarian ablation and gonadotropin-releasing hormone agonists

Junhan Jiang1†, Junnan Xu2†, Li Cai3, Li Man4, Limin Niu5, Juan Hu6, Tao Sun2* and Xinyu Zheng1*

Abstract

Background: Ovarian function suppression (OFS) is indicated in premenopausal women with early or metastasis breast cancer, which may be achieved with similar effect by gonadotropin-releasing hormone agonists (GnRHa) or ovarian ablation (OA). We examined whether there were differences in major depressive symptoms outcomes and its associated factors between gonadotropin-releasing hormone agonists (GnRHa) and ovarian ablation (OA) in premenopausal breast cancer patients.

Methods: Premenopausal breast cancer patients from seven hospitals who received OFS participated in the study between June 2019 and June 2020. The correlated variable was the type of ovarian suppression, categorized as either OA (n = 174) or GnRHa (n = 389). Major depressive symptoms was evaluated using the Patient Health Questionnaire (PHQ-9), and the Female Sexual Function Index questionnaire was used to assess sexual function.

Results: A total of 563 patients completed the surveys. The mean PHQ-9 sum score was slightly lower in the GnRHa cohort than in the OA cohort (11.4 ± 5.7 vs. 12.8 ± 5.8, P = 0.079). There were significantly fewer patients with major depressive symptoms (PHQ-9 ≥ 15) in the GnRHa cohort (31.1% vs. 40.2%, Exp (B) = 1.805, P = 0.004). Further, breast-conserving surgery and sexual dysfunction were negatively correlated with major depressive symptoms [mastectomy vs. breast-conserving: Exp (B) = 0.461, P <0.001; [sexual dysfunction vs. normal: Exp (B) = 0.512, P = 0.001].

Conclusions: This is the first study to demonstrate that GnRHa results in more favorable depressive symptoms outcomes than OA. Moreover, most patients preferred alternatives to their OFS treatment. These findings can contribute to improving and alleviating the adverse effects of OFS.

*Correspondence: jianong@126.com; xyzheng@cmu.edu.cn
†Junhan Jiang and Junnan Xu contributed equally to this work.
1 Department of Breast Surgery, First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning, China
2 Department of Breast Medicine, Cancer Hospital of China Medical University, Liao Ning Cancer No.44 Xiaoheyuan Road, Dadong District, Shenyang, Liao Ning 110042, People’s Republic of China
Full list of author information is available at the end of the article
Keywords: Breast cancer, ovarian function suppression, major depressive symptoms, sexual dysfunction, quality of life

Background

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths among women worldwide. In China, there has been a marked increase in the breast cancer incidence among younger women [6]. An increasing number of premenopausal Chinese patients aged 45–55 years are being diagnosed with breast cancer, and approximately 6% of patients diagnosed with breast cancer are below 40 years of age [7]. In recent decades, extended adjuvant endocrine therapy, using ovarian function suppression (OFS) has been administered to premenopausal breast cancer patients, with beneficial results for the hormone receptor (HR) -positive population [46]. Depressive symptoms have been identified as one of the most common complications in patients with breast cancer. Depression is correlated with diagnosis, the types of treatment, and adverse effects in breast cancer patients [34]. It has been shown depression might be an critical factor for prognosis and breast cancer recurrence in patients with early breast cancer [44]. Young breast cancer survivors who undergo mastectomy surgery are likely to have worse sexual health, body image and depression compared with women undergoing breast-conserving surgery [36]. However, few studies have compared the impacts of OFS on major depressive symptoms using either ovarian ablation (OA) or gonadotropin-releasing hormone agonists (GnRHa).

OFS, which can eliminate or reduce ovarian estrogen production, was the first endocrine therapy to be investigated for use in premenopausal breast cancer patients. Initially, OFS was achieved through surgical bilateral oophorectomy or ovarian irradiation [24, 27]. However, more recently, GnRHa (also known as luteinizing hormone-releasing hormone agonists) has been used to achieve this outcome [33, 37]. Real-world use of ovarian irradiation for OFS has been limited in China. Consequently, only patients undergoing surgical bilateral oophorectomy or receiving GnRHa were enlisted in this comparative study.

It is now well established that the effect of OFS in reducing the risk of breast cancer relapse or distant metastases is similar to that of the older cyclophosphamide, methotrexate, and fluorouracil regimen [32]. The findings of the Suppression of Ovarian Function Trial (SOFT) indicated that when combined with tamoxifen, OFS had greater benefits for premenopausal women aged <35 years with a high risk of relapse and that a combination of OFS with exemestane increased this benefit [9, 10, 28]. There is an urgent need to explore the use of GnRHa for OFS for protecting ovarian function and improving fertility outcomes following the adverse effects of chemotherapy [3]. Moreover, it is important for clinicians to help patients to understand and protect their ovarian function prior to receiving chemotherapy [1, 38].

A comprehensive analysis of the SOFT results revealed that OFS combined with GnRHa has a similar effect to OA but with clear advantages for premenopausal women [14, 30, 39]. First, GnRHa has reversible effects and can be discontinued if the patient experiences intolerable symptoms. Thus, GnRHa may be preferred over permanent OA by bilateral oophorectomy or ovarian irradiation. All OFS techniques contribute to premature ovarian failure, which has significant consequences, including infertility, sexual dysfunction, and vasomotor symptoms [13, 42]. However, to date, there has been little discussion of emotional disorders, such as major depressive symptoms or sexual dysfunction, associated with the deployment of different OFS strategies. This study examined whether GnRHa is superior to OA in terms of the incidence of major depressive symptoms in premenopausal patients with breast cancer.

Methods

Participants

We conducted an anonymous, cross-sectional study between July 2019 and June 2020 at seven hospitals across China. Eligible participants were female breast cancer patients who had either OA by bilateral oophorectomy or GnRHa by one of the following methods: monthly intravenous doses of 3.6 mg of goserelin acetate (Zoladex, AstraZeneca) or monthly intravenous doses of 3.75 mg of leuprolrel acetate (Leuplin, Takeda) or an intramuscular injection of 11.25 mg of leuprolrel acetate once every three months. Indications for ovarian function inhibition in breast cancer patients included premenopausal with either early or metastatic disease. In early breast cancer, endocrine therapy containing OFS is recommended for high-risk premenopausal hormone receptor-positive breast cancer, and should be considered for moderate risk patients. In metastatic hormone receptor-positive breast cancer, all the premenopausal patients should be converted to postmenopausal status and received endocrine therapy. Bilateral ovarian ablation and medical GnRHa had the similar effect and were superior to ovarian radiotherapy. Therefore, either bilateral ovarian ablation or medical GnRHa is indicated in
Premenopausal women with hormone receptor-positive breast cancer. The eligible participants were invited to complete the Breast Cancer Survivorship Ovarian Function Suppression Survey (OFS-Q5), an online questionnaire that included the Patient Health Questionnaire 9 (PHQ-9), which is an instrument for screening depressive symptoms, and the Female Sexual Function Index (FSFI) questionnaire. The validity and reliability of the Chinese versions of these questionnaires have been previously demonstrated \[19, 45, 47\]. The study was anonymized to improve the participation rate and accuracy of the responses.

**Included criteria and exclusion criteria**

Participants fitting the following criteria were included in our study: (1) a clear diagnosis of breast cancer (tissue or cell diagnosis), (2) age >18 years, and (3) recipient of OFS via surgical bilateral oophorectomy or GnRHa. The exclusion criteria were as follows: (1) refusal to provide informed consent, (2) inability to understand the questionnaires, and (3) undergoing ovarian irradiation. Written informed consent was obtained from each participant, and the study protocols were reviewed and approved by the ethics committee of the Cancer Hospital of China Medical University (protocol RB no. 20190545). The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Questionnaire and data gathering**

The questionnaire was divided into four sections. The first section mostly comprised items for obtaining the respondents’ demographic and clinical characteristics, the second section recorded OFS information, and the following two sections respectively evaluated major depressive symptoms and sexual function in both cohorts. Two assistants were trained to develop a knowledge base and communication skills related to OFS and breast cancer. The first assistant explained and confirmed the information, step by step, with the patients, and the second assistant reconfirmed the responses via telephone 3–10 days after the survey’s implementation. The questionnaire was in Chinese, which was the respondents’ native language.

**Depressive symptoms questionnaire**

As previously noted ([16]), in PHQ-9 questionnaire, each of the nine items was assigned a score of 0–3, and the scores were then summed to obtain the final score. The following PHQ-9 score ranges have been recommended for determining levels of depression: 0–7: none and/or mild, 8–14: moderate, 15–19: moderate to severe, and 20–27: severe. Lower scores indicate better emotional functioning, whereas a sum score of ≥15 indicates major depression.

**Sexual function questionnaire**

Sexual function was quantified using the FSFI questionnaire (Isidori AM et al 2010), which is a 19-item survey instrument that specifically assesses six sexual functioning domains (FSFI-1: desire, FSFI-2: arousal, FSFI-3: lubrication, FSFI-4: orgasm, FSFI-5: satisfaction, and FSFI-6: pain).

**Statistical methods**

Data analysis was performed using the IBM SPSS Statistics for Windows, version 23.0 software package (IBM Corp., Armonk, N.Y., USA). Fisher’s exact test was used for categorical data. Differences in age and OFS duration were analyzed using unpaired t-tests. The means of the PHQ-9 total scores, FSFI total scores, and FSFI subscores were subjected to nonparametric Mann–Whitney U tests to determine whether the data were normally distributed. The multivariate analysis was performed with logistics analysis. P values < 0.05 indicated statistical significance.

**Results**

**Patient characteristics**

As shown in Fig. 1, the final sample of patients with complete demographic characteristics and PHQ-9/FSFI scores comprised 563 individuals. Of these patients, 174 had undergone OA and 389 were being given GnRHa for OFS. Table 1 lists the main characteristics of the GnRHa and OA cohorts. The patients’ median ages in the OA and GnRHa cohorts were 46.0 and 43.0 years, respectively.

Table 1 shows that the time lapse from the commencement of ovarian suppression was significantly longer in the OA cohort than in the GnRHa cohort (30.3 ± 29.1 months vs. 22.8 ± 22.1 months, P = 0.003). The majority of respondents had low annual incomes (77.0%), had estrogen receptor or progesterone receptor positive breast cancers (97.2%), and were human epidermal growth factor receptor-2 (HER2)-negative (76.1%). In addition, 57.9% of the patients in the GnRHa cohort were educated up to or above college level, whereas the corresponding percentage for the OA cohort was only 40.8%. Patients receiving GnRHa favored breast-conserving surgery (26.0% vs. 16.7%, P = 0.016).

**Major depressive symptoms in the GnRHa and OA cohorts**

The results shown in Table 2 reveal that the mean PHQ-9 sum score of the GnRHa cohort was lower than that of the OA cohort (11.4 ± 5.7 vs. 12.8 ± 5.8, P = 0.079). According to the treatment algorithm for
depressive symptoms, 36.2% (63/174), 28.2% (49/174), and 12.6% (22/174) of the patients in the OA cohort were respectively categorized in the moderate, major, and severe depressive symptoms groups. Notably, there were significantly fewer patients with major depressive symptoms (PHQ-9 ≥ 15) in the GnRHa cohort than in the OA cohort. A positive correlation was found between major depressive symptoms and OA, and the absolute difference was approximately 9.1 percentage points (31.1% vs. 40.2%, \( P = 0.025 \)). Item-level responses indicated that 15 of the 174 patients who underwent OA and 30 of the 389 patients taking GnRHa experienced suicidal ideation, which is considered as a symptom of major depressive symptoms, but this difference was not statistically significant (8.6% vs. 7.7%, \( P = 0.713 \)).

**Sexual dysfunction in the GnRHa and OA cohorts**

As shown in Table 3, patients receiving GnRHa had lower mean and median FSFI scores than patients who had undergone OA (mean: 17.8 ± 8.7 vs. 19.3 ± 8.5, \( P = 0.205 \); median: 17.8 vs. 19.6). The results for sexual dysfunction, which was defined as FSFI < 23, revealed that there was strong evidence of GnRHa-induced sexual dysfunction; 61.5% of OA patients met the criteria for sexual dysfunction compared with 72.2% of patients receiving GnRHa (\( P = 0.011 \)). According to the data shown in Fig. 2, patients receiving GnRHa had slightly
lower scores on most of the FSFI sub-scores compared with the scores of patients who had undergone OA. However, their scores in the pain section were significantly lower (FSFI-6 scores: mean ± SD: 3.3 ± 2.2 vs. 2.5 ± 2.2, \( P = 0.007 \)), and there were also significant differences in scores of the item on lubrication (FSFI-3 scores: mean ± SD: 3.5 ± 2.5 vs. 2.9 ± 2.6, \( P = 0.048 \)).

### Table 1  Baseline social demographics and clinical characteristics in breast cancer patients with ovarian function suppression

| Characteristics                      | Total | Ovarian Ablation OA | GnRH agonist GnRHa | t or \( \chi^2 \) value | \( P \) Value |
|--------------------------------------|-------|---------------------|--------------------|--------------------------|--------------|
| N                                    | 563   | 174                 | 389                |                          |              |
| Age, years                           |       |                     |                    |                          |              |
| Median                               | 44    | 46                  | 43                 |                          |              |
| Range                                | 22-63 | 30-57               | 22-63              |                          |              |
| Mean (SD)                            | 42.9 ± 7.7 | 45.2 ± 6.7        | 41.8 ± 7.8         | 5.374                    | <0.001       |
| Duration of OFS                      |       |                     |                    |                          |              |
| Mean (SD), months                    | 25.1 ± 25.4 | 30.3 ± 29.1       | 22.8 ± 22.1        | 3.009                    | 0.003        |
| Educational level                    |       |                     |                    |                          |              |
| High school or below                 | 268   | 103                 | 165                | 13.570                   | 0.00002      |
| College or above                     | 295   | 71                  | 224                |                          |              |
| Annual income (RMB)                  |       |                     |                    |                          |              |
| \( \leq 50,000 \)                     | 398   | 126                 | 272                | 0.360                    | 0.548        |
| \( > 50,000 \)                       | 165   | 48                  | 117                |                          |              |
| Smoking habit                        |       |                     |                    |                          |              |
| Never or little                      | 548   | 168                 | 380                | 0.597                    | 0.440        |
| Mostly                               | 15    | 6                   | 9                  |                          |              |
| Alcohol drinking habit               |       |                     |                    |                          |              |
| Never or little                      | 556   | 170                 | 386                | 1.210                    | 0.271        |
| Mostly                               | 7     | 4                   | 3                  |                          |              |
| Co-morbidity                         |       |                     |                    |                          |              |
| Diabetes/Hypertension                | 43    | 14                  | 29                 | 0.060                    | 0.807        |
| None                                 | 520   | 160                 | 360                |                          |              |
| Type of Surgery                      |       |                     |                    |                          |              |
| Mastectomy                           | 433   | 145                 | 288                | 5.852                    | 0.016        |
| Breast-conserving                    | 130   | 29                  | 101                |                          |              |
| TNM staging                          |       |                     |                    |                          |              |
| I-III                                | 400   | 110                 | 290                | 7.505                    | 0.006        |
| IV                                   | 163   | 64                  | 99                 |                          |              |
| Hormone Receptor Status              |       |                     |                    |                          |              |
| ER or PR Positive                    | 526   | 153                 | 373                | 12.393                   | 0.0004       |
| ER and PR Negative                   | 37    | 21                  | 16                 |                          |              |
| HER2 Status                          |       |                     |                    |                          |              |
| Positive                             | 130   | 35                  | 95                 | 1.256                    | 0.262        |
| Negative                             | 433   | 139                 | 294                |                          |              |
| ET+OFS                               |       |                     |                    |                          |              |
| AI                                   | 395   | 115                 | 280                | 0.009                    | 0.924        |
| TAM                                  | 86    | 20                  | 66                 |                          |              |
| Ful                                  | 46    | 19                  | 27                 |                          |              |
| None                                 | 36    | 20                  | 16                 |                          |              |

**Associated factors for major depressive symptoms in patients with OFS**

The data in Table 4 and 5 show that the type of ovarian suppression was closely associated with major depressive symptoms in the univariate and multivariate analyses (OA vs. GnRHa: Exp (B) = 1.805 [95% CI: 1.204–2.705], \( P = 0.004 \)). As noted above, patients receiving GnRHa favored breast-conserving surgery.
Table 2: Depressive symptoms (PHQ-9) by the type of ovarian function suppression in patients with breast cancer

| Ovarian Ablation (OA) n, (%) | Ovarian function suppression | t or χ² value | P value |
|-------------------------------|-------------------------------|--------------|--------|
| Total                         | 174                          | 389          |        |
| PHQ-9 scores Median(IQR)      | 13 (8.0-17.0)                | 11 (7.0-16.0) |        |
| PHQ-9 scores Range            | 1-24                         | 0-25         |        |
| PHQ-9 scores Mean (SD)        | 12.8 ± 5.8                   | 11.4 ± 5.7   | 1.892  | 0.059 |
| PHQ-9 scores subgroups        |                              |              |        |
| None or mild (0-7), n(%)      | 40 (23.0)                    | 101 (26.0)   |        |
| Moderate (8-14), n(%)         | 63 (36.2)                    | 167 (42.9)   |        |
| Major (15-19), n(%)           | 49 (28.2)                    | 87 (22.4)    |        |
| Severe (20-27), n(%)          | 22 (12.6)                    | 34 (8.7)     |        |
| Major Depression              |                              |              |        |
| (PHQ≥15), n(%)                | 71 (40.8)                    | 121 (31.1)   | 5.033  | 0.025 |
| Suicidal ideation, n(%)       | 15 (8.6)                     | 30 (7.7)     | 0.135  | 0.713 |

PHQ-9 Patient Health Questionnaire - 9 items, SE Standard errors, IQR Interquartile range (25th, 75th percentiles).

Table 3: Sexual function by the type of ovarian function suppression in patients with breast cancer

| Ovarian function suppression           | Ovarian Ablation (OA) | GnRH agonist (GnRHa) | t or χ² value | P value |
|----------------------------------------|-----------------------|----------------------|--------------|--------|
| FSI total scores                       |                       |                      |              |        |
| Mean (SD)                              | 19.3 ± 8.5            | 17.8 ± 8.7           | 0.205        |        |
| Median (IQR)                           | 19.6(13.0-26.7)       | 17.8(12.2-24.3)      |              |        |
| Range                                  | 2-34                  | 2-34                 |              |        |
| Sexual dysfunction (FSFI<23), n(%)     | 107 (61.5)            | 281 (72.2)           | 6.476        | 0.011  |

FSFI Female sexual function index, SE Standard errors, IQR Interquartile range (25th, 75th percentiles).

Fig. 2: Comparison of responses to sub-items on sexual function provided by women in the GnRHa and OA cohorts. Notes: FSFI-1: desire; FSFI-2: arousal; FSFI-3: lubrication; FSFI-4: orgasm; FSFI-5: satisfaction; FSFI-6: pain. Abbreviations: OA = ovarian ablation; GnRHa = gonadotropin-releasing hormone agonists
(26.0% vs. 16.7%, \( P = 0.015 \)). Mastectomy breast surgery was negatively correlated with major depressive symptoms in the multivariate analysis (Mastectomy vs breast-conserving: \( \text{Exp (B)} = 0.461, 95\% \text{ CI} 0.301-0.707, P < 0.001 \)). As mentioned in Table 4, patients with fulvestrant combined with OFS had less major depressive symptoms in the univariate analysis. Nonetheless, the combined ET was not significantly correlated with major depressive symptoms (sexual dysfunction vs. normal: \( \text{Exp (B)} = 0.512 [95\% \text{ CI}: 0.348-0.752], P = 0.001 \)).

### Table 4  Clinical characteristics in breast cancer patients with major depressive symptoms

| Characteristics                              | Major depressive symptoms (PHQ≥15) | Normal (PHQ<15) | \( \chi^2 \) value | \( P \) Value |
|----------------------------------------------|-----------------------------------|-----------------|--------------------|---------------|
| N                                            | 191                               | 372             | 1.624              | 0.202         |
| Age, years                                   |                                   |                 |                    |               |
| \( \leq 45 \)                                | 118                               | 209             | 1.519              | 0.218         |
| \( > 45 \)                                   | 73                                | 163             |                    |               |
| Educational level                            |                                   |                 |                    |               |
| High school or below                         | 84                                | 184             | 0.157              | 0.692         |
| College or above                             | 107                               | 188             |                    |               |
| Annual income (RMB)                          |                                   |                 |                    |               |
| \( \leq 50,000 \)                             | 133                               | 265             | 13.969             | <0.001        |
| \( > 50,000 \)                               | 58                                | 107             |                    |               |
| Type of Surgery                              |                                   |                 |                    |               |
| Mastectomy                                   | 129                               | 304             |                    |               |
| Breast-conserving                            | 62                                | 68              |                    |               |
| TNM staging                                  |                                   |                 | 0.019              | 0.890         |
| I-III                                        | 135                               | 265             |                    |               |
| IV                                           | 56                                | 107             |                    |               |
| Hormone Receptor Status                      |                                   |                 | 0.039              | 0.843         |
| ER or PR Positive                            | 179                               | 347             |                    |               |
| ER and PR Negative                           | 12                                | 25              |                    |               |
| HER2 Status                                  |                                   |                 | 2.114              | 0.146         |
| Positive                                     | 51                                | 79              |                    |               |
| Negative                                     | 140                               | 293             |                    |               |
| Type of OFS                                  |                                   |                 | 4.442              | 0.035         |
| GnRH agonist                                 | 121                               | 268             |                    |               |
| Ovarian Ablation                             | 70                                | 104             |                    |               |
| OFS Time                                     |                                   |                 | 0.059              | 0.809         |
| \( \leq 2 \) years                          | 116                               | 222             |                    |               |
| \( > 2 \) years                              | 75                                | 150             |                    |               |
| OFS+ET                                       |                                   |                 | 3.069              | <0.080        |
| AI/SERM                                      | 128/30                            | 267/56          |                    |               |
| Ful                                          | 21                                | 25              |                    |               |
| Sexual dysfunction                           |                                   |                 | 11.146             | 0.001         |
| No                                           | 84                                | 111             |                    |               |
| Yes                                          | 107                               | 261             |                    |               |

**Alternative to OFS treatment**

In the final part of the questionnaire, respondents were asked if they would choose to change to another kind of OFS. For example, “Would you choose OA instead of GnRHa or vice versa?” The majority of the respondents in both cohorts viewed this change positively. Approximately both more than half of the patients in both cohorts opted to change the type of OFS (GnRHa: 62.7% vs. OA: 60.8%). For concerns that costs could affect the
Table 5. The associated factors on major depressive symptoms (PHQ-9, scores <15 vs ≥15) by multivariate logistic regression in patients with breast cancer

| Characteristics       | multivariate |   |   |   |
|-----------------------|--------------|---|---|---|
|                       | B            | Wald | P value | Exp(B) | 95%CI       |
| Type of Surgery       | -0.774       | 12.570 | <0.001 |       |            |
| Breast-conserving     | 1            |       |         |       |            |
| Mastectomy            | 0.461        | 0.301-0.707 | 0.004 |       |            |
| Type of OFS           | -0.590       | 8.178  | 0.004  |       |            |
| GnRH agonist          | 1            |       |         |       |            |
| Ovarian Ablation      | 1.805        | 1.204-2.705 | 0.001 |       |            |
| OFS+ET                | -0.329       | 1.013  | 0.314  |       |            |
| AI/SERM               | 1            |       |         |       |            |
| Ful                   | 0.720        | 0.379-1.366 | 0.12  |       |            |
| Sexual dysfunction    | -0.670       | 11.620 | 0.001  |       |            |
| No                    | 1            |       |         |       |            |
| Yes                   | 0.512        | 0.348-0.752 | 0.001 |       |            |

As shown in our study, may offer a multidimensional perspective on emotional disorders.

Our results for major depressive symptoms confirmed our hypotheses and endorsed previous findings [2, 19]. Young breast cancer survivors are often at the greatest risk of experiencing major depressive symptoms because of the potential concerns about abrupt menopause and breast disease to relapse, and the incidence of major depressive symptoms among them would be expected considerably higher than the general cohort of the same age range. One meta-analysis of four studies covering 3,373 patients revealed that the difference in depressive symptoms levels between those undergoing OFS and those not undergoing OFS was insignificant (RR: 1.28, 95% CI: 0.94–1.74, P = 0.12), with no significant heterogeneity among the studies (P = 0.46, I² = 0%) [25]. In our investigation, we focused on major depressive symptoms and its potential correlated factors in women with early and metastatic breast cancer. Depression can be linked to both the psychological aspects of social relationships and the physical effects of chemotherapy, can be overwhelming during treatment of metastatic breast cancer [29]. Whether psychiatric disorders will affect the sexual function in breast cancer patients remains an open-ended question with inconsistent results. Young breast cancer survivors who undergo mastectomy surgery have worse sexual health, body image and depression degree compared with women undergoing breast-conserving surgery [36]. In our study, patients with breast-conserving surgery had lower level of major depressive symptoms. The results may indicated major depressive symptoms was correlated with multiple factors and the patients taking OA or mastectomy surgery may be more likely to suffer from major depressive symptoms.

The administration of GnRH to premenopausal women to reduce estrogen levels can increase the risk of vaginal dryness and dyspareunia [22], which might cause and aggravate sexual dysfunction. Whereas aromatase inhibitors have similar sexual dysfunction effects, they are rarely administered to premenopausal women without OFS. Unlike OA-related sexual dysfunction issues, those associated with GnRH may be reversible after treatment cessation. However, ovarian failure caused by OA or chemotherapy is permanent [18]. Our results indicated that sexual dysfunction was more common and serious among women in the GnRH cohort than those in the OA cohort regardless of the duration of the OFS. Notably, the respondents’ mean age within the GnRH cohort was lower than that of respondents in the OA cohort and more women in the OA cohort may have reached menopause than those in the GnRH cohort. Studies on cancer care have reported young survivors have low sexual desire, who are more likely to be distressed.

Discussion

We conducted a cross-sectional investigation to explore the association between depressive symptoms and the type of OFS (OA or GnRHa) administered to breast cancer patients in seven hospitals. Our results demonstrated that the GnRHa cohort presented with lower levels of major depressive symptoms compared with the OA cohort. This is the first cross-sectional study to provide a direct comparison of levels of serious major depressive symptoms in breast cancer patients undergoing OA and GnRHa. Differing from other studies that used Common Terminology Criteria for Adverse Events (CTCAE) grades to assess the negative effects of OFS, we used PHQ-9 scores in our study. For instance, Moore et al. [25] found that adverse effects identified in early breast cancer patients included eight cases of grade-2 emotional disorders and one case of grade-3 emotional disorders in their OFS cohort compared with three cases of grade-2 emotional disorders in the non-OFS cohort. PHQ-9 questionnaire were used to evaluate major depressive symptoms, and the majority of participants were reluctant to receive OA because of its cost.
by alterations to their appearance than older women [35]. The observed inconsistencies may be attributed to the unequal age distribution within our cohorts [35] and, specifically, spontaneous age-related decline in sexual desire. Previous studies have suggested that the association between tamoxifen and sexual dysfunction remains controversial in premenopausal patients [12, 15, 40, 41]. Fulvestrant may cause lower major depressive symptoms compared with AI or SERM, nonetheless, fulvestrant was only indicated in metastasis breast cancer and the sample was small. We further to pay close attention to sexual dysfunction and major depressive symptoms in patients with diverse combined endocrine therapy.

Limitations of the study
There were inherent limitations in the cross-sectional design of the study, as indicated below. First, because the survey was anonymized, all treatment information was based on patient recall and could not be re-checked for accuracy using medical records. Therefore, the reporting may not have been sufficiently accurate for making reliable evaluations based on the patients’ responses to the questionnaires alone. A fully prospective evaluation may provide additional information and limit recall bias.

Second, the cross-sectional design constrains us from drawing cause-and-effect conclusions regarding major depressive symptoms and sexual dysfunction. While the reliability and validity of the Chinese versions of the three questionnaires have previously been confirmed [19, 20, 43, 45, 47], we cannot ignore the possibility of social bias given by the methods of delivering the questionnaire and retrieving the responses. Two assistants confirmed the responses with the patients face to face and by telephone in an attempt to reduce the possibility of bias. Additionally, we were unable to evaluate the presence or absence of sufficient ovarian suppression in the GnRHa cohort in our study. Thus, whether or not insufficient ovarian suppression affects major depressive symptoms, sexual dysfunction, and quality of life thus remains unclear. Nevertheless, in spite of its exploratory nature, this study offers some insights into the management of the individual adverse effects of OFS.

Further research will focus on the following three aspects, firstly, whether the different endocrine therapy or chemotherapy will affect the efficacy or depressive symptoms, sexual dysfunction of OFS. Our small sample research indicated the breast cancer patients previous received OFS combined AI suffered from serious vaginal dryness and sexual dysfunction, greatly improved its symptom after changing to OFS combined with tamoxifen. A large and prospective study need to be investigate the correlation and its mechanism. Moreover, the multi-factors investigation may be helpful to provide the optimal OFS type and the patients get the more efficacy benefit and less adverse affects. Last but not least, how to improve major depressive symptoms or sexual dysfunction in patients receiving OFS therapy and presented these symptoms. We have carried out psychological counseling combined with essential oil including jasminum sambac, pelargonium graveolens and leptospermum scoparium in patients with sexual dysfunction. The results will be expected to optimize management of the patients and improve the outcomes.

Conclusion
We highlight a greater prevalence of major depressive symptoms in patients who had undergone OA than those receiving medically administered GnRHa. This finding indicates that medical GnRHa is a simple, reversible, and preferable therapy for OFS in patients with breast cancer. Further research that examines the closer links between major depressive symptoms and OFS is evidently needed. Moreover, studies should highlight the adverse effects of OFS in premenopausal breast cancer patients. Further, the routine application of a personalized approach seems to be warranted.

Abbreviations
CTCAE: Common Terminology Criteria for Adverse Events; FSFI: Female Sexual Function Index; GnRHa: gonadotropin-releasing hormone agonists; OA: ovarian ablation; OFS: ovarian function suppression; PHQ-9: Patient Health Questionnaire 9; SOFT: Suppression of Ovarian Function Trialgonadotropin-releasing hormone agonists (GnRHa) and ovarian ablation (OA).

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12888-021-03611-6.

Authors’ contributions
XZ, and TS: Conceived and designed the experiments. JX, LC, LM, LN, JH performed the survey. JI and JX analyzed the data. JX wrote the draft of paper. All authors read and approved the final manuscript and submission of this manuscript.

Funding
This study were partly funded by the Natural Science Foundation of Liaoning Province (No. 20180511215, XZ), Key R & D guidance plan of Liaoning Province (2019HJ0/10300020, XZ), Key Research Project of Liaoning (grant number 2018225076, ST), CSCO Project (Y-2019Genecast-019, JX, Y-HR2018-362, TS), Wujieping Project (320675018541, TS) and Liaoning Revitalization Talents Program (XY1C1907160, JX). Funding was used for participants’ inconvenience fees, and printing of publicity materials. The funders have not participated in
the design of the study and collection, analysis, or interpretation of data or in writing the manuscript.

Availability of data and materials
The datasets generated and analysed during the current study are not publicly available due further research but are available from the corresponding author on reasonable request.

Declaration

Ethics approval and consent to participate
This study was conducted in full conformance with the International Conference for Harmonization (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki. A written informed consent was obtained from each participant and the study protocols were reviewed and proved by the Ethic Committee of Cancer Hospital of China Medical University (protocol number R8 #20190545). All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1. Department of Breast Surgery, First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Heping District, Shenyang 110001, Liaoning, China. 2. Department of Breast Medicine, Cancer Hospital of China Medical University, Liaohe Hospital No.44 Xucheyuan Road, Dadong District, Shenyang, Liaoning 110042, People’s Republic of China. 3. The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150040, China. 4. Department of Medical Oncology, Anshan Cancer Hospital, Anshan 114000, China. 5. Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450003, China. 6. Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha 410000, China.

Received: 22 January 2021   Accepted: 22 November 2021

Published online: 11 December 2021

References
1. Allaway HCM, Chizen DR, Adams GP, et al. Effects of a single 20 mg dose of letrozole on ovarian function post dominant follicle selection: An exploratory randomized controlled trial. J Ovarian Res. 2017;10:6. https://doi.org/10.1186/s13048-017-0303-x.
2. Alshehre SM, Duffy S, Jones G, et al. A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain. Reprod Biol Endocrinol. 2020;18(28). https://doi.org/10.1186/s12958-020-00586-z.
3. Blumenfeld Z. Fertility preservation using GnRH agonists: Rationale, possible mechanisms, and explanation of controversy. Clin Med Insights Reprod Health. 2019;13:1179558119870163. https://doi.org/10.1177/1179558119870163.
4. Bober SL, Fine E, Recklitis CJ. Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): A clinical intervention for young breast cancer survivors. J Cancer Surviv. 2020;14:26–30. https://doi.org/10.1007/s13276-019-10080-x.
5. Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103:4146–54. https://doi.org/10.1210/jc.2018-01345.
6. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438–51. https://doi.org/10.3322/caac.21583.
7. Fan L, Strasser-Weippl KU, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. https://doi.org/10.1016/S1470-224X(13)70567-9.
8. Flynn KE, Reese JB, Jeffrey D, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology. 2012;21:594–601. https://doi.org/10.1002/pon.1947.
9. Francis PA, Pagani O, Fleming GF, et al. SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoai1803164.
10. Francis PA, Regan MM, Fleming GF, et al. SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436–46. https://doi.org/10.1056/NEJMoa1412379.
11. Fugger G, Dold M, Bartova L, et al. Major depression and comorbid diabete -Findings from the European Group for the Study of Resistant Depressio. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109638.
12. Gandhi C, Butler E, Pesek S, et al. Sexual dysfunction in breast cancer survivors: Is it surgical modality or adjuvant therapy? Am J Clin Oncol. 2019;42:500–6. https://doi.org/10.1097/OCO.0000000000000552.
13. Hsieh AH, Kichenadasse G, Vatandoust S, et al. Goserelot toxieities and preferences for ovarian suppression method in pre-menopausal women with breast cancer. Intern Med J. 2016;46:1153–9. https://doi.org/10. 1111/imj.13156.
14. Huerta-Reyes M, Maya-Núñez G, Pérez Solís MA, et al. Treatment of breast cancer with gonadotropin-releasing hormone analogs. Front Oncol. 2019;9:943. https://doi.org/10.3389/fonc.2019.00943.
15. Hummel SB, Hahn DEE, van Lankveld JJD, et al. Factors associated with specific diagnostic and Statistical Manual of Mental Disorders, Fourth Edition sexual dysfunctions in breast cancer survivors: A study of patients and their partners. J Sex Med. 2017;14:1248–59. https://doi.org/10.1016/j.jsem.2017.08.004.
16. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. https://doi.org/10.1046/j.1525-1497.2001.0160009606.x.
17. Kurt K, Spitzer RL, Williams Janet BW, et al. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psych. 2010;32(4):345–59. https://doi.org/10.1016/j.genhospsy.2010.03.006.
18. Kuehn R, Casabon J, Raker C, et al. Sexual dysfunction in survivorship, the impact of menopause and endocrine therapy. Ann Surg Oncol. 2019;26:3159–65. https://doi.org/10.1186/s10434-019-07552-z.
19. Lan B, Jiang S, Li T, et al. Depression, anxiety, and their associated factors among Chinese early breast cancer in women under 35 years of age: A cross sectional study. Curr Probl Cancers. 2020;100558. https://doi.org/10.1016/j.cancer.2020.100558.
20. Li L, Yang B, Li H, et al. Chinese multicentre prospective registry of breast cancer patient-reported outcome-reconstruction and oncoplastic cohort (PRO-ROC): A study protocol. BMJ Open. 2019;9(12):e032945. https://doi.org/10.1136/bmjopen-2019-032945.
21. Isidori AM, Pozza C, Esposito K, et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010;7(3):1139–46. https://doi.org/10.1111/j.1743-6109.2009.01613.x.
22. Kurtkum T, Yilmazli S, Keskin E, et al. Impact of sexual dysfunction on quality of life in breast cancer patients undergoing surgery. J Sex Med. 2019;16:2005–13. https://doi.org/10.1016/j.jsm.2019.03.006.
23. Mahmoud R, Wainwright SR, Chaiton JA, et al. Ovarian hormones, but not ovariectomy, impact resilience within a chronic unpredictable stress model in middle-aged female rats. Neuropharmacology. 2016;107:278–93. https://doi.org/10.1016/j.neuropharm.2016.01.033.
24. Metwally H, Hamdy O, Elbalka SS, et al. Oophorectomy as a hormonal ablation therapy in metastatic and recurrent breast cancer. Current indications and results. Indian J Surg Oncol. 2019;10:542–6. https://doi.org/10.1055/s-0039-1686938.
25. Moore HC, Unger JM, Phillips KA, et al., POEMS/S0230 Investigators (2015) Goserelot for ovarian protection during breast-cancer adjuvant chemother. J Clin Endocrinol Metab. 2015;100:500–6. https://doi.org/10.1073/COC.0000000000000552.
26. Nguyen TV, Reuter JM, Gaikwad NW, et al. The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist- induced ovarian suppression: Effects of estradiol and progesterone.

Page 10 of 11Jiang et al. BMC Psychiatry (2021) 21:624
addback. Transl Psychiatry. 2017;7(8):e1193. https://doi.org/10.1038/tp.2017.146.

27. Nourmousavi M, Pansegrau G, Popesku J, et al. Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. Breast Cancer Treat Rev. 2017;55:26–35. https://doi.org/10.1016/j.bctrv.2017.02.005.

28. Pagani O, Francis PA, Fleming GF, et al. SOFT and TEXT Investigators and International Breast Cancer Study Group (2019) Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women. Results from SOFT and TEXT. J Clin Oncol 38:1293–1303.https://doi.org/10.1200/JCO.18.01967

29. Park EM, Gelber S, Rosenberg SM, et al. Anxiety and depression in young women with metastatic breast cancer: A cross-sectional study. Psychosomatics. 2018;59:251–8. https://doi.org/10.1016/j.psym.2018.01.007.

30. Park YH, Kim TY, Kim GM, et al.; Korean Cancer Study Group (KCSG). (2019) Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capcitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 20:1750-1759. https://doi.org/10.1016/S1470-2045(19)30565-0

31. Pooley AE, Benjamin RC, Sreedhar S, et al. Sex differences in the traumatic stress response: The role of adult gonadal hormones. Biol Sex Differ. 2018;9(1):32. https://doi.org/10.1186/s13293-018-01928-8

32. Recchia F, Candeloro G, Rosselli M, et al. Adjuvant ovarian suppression, high-dose chemotherapy and immunotherapy for premenopausal patients with high-risk breast cancer. Anticancer Res. 2015;35:6847–53.

33. Regan NM, Fleming GF, Walley B, et al. Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: Lights and shadows. J Clin Oncol. 2019;37(11):862–6. https://doi.org/10.1200/JCO.18.02433.

34. Ribi K, Luo W, Walley B, et al. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2018;181(2):347–59. https://doi.org/10.1007/s10549-018-05622-5.

35. Robinson PJ, Bell RJ, Christakis MK, et al. Aromatase inhibitors are associated with low sexual desire causing distress and fecal incontinence in women: An observational study. J Sex Med. 2017;14:1566–74. https://doi.org/10.1016/j.jsxm.2017.09.018.

36. Rosenberg S, Dominicini L, Gelber S, et al. Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. JAMA Surg. 2020;155(11):1035–42. https://doi.org/10.1001/jamasurg.2020.3325.

37. Sa-Nguanraksa D, Kisorakun T, Pongthong W, et al. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer. Mol Clin Oncol. 2019;11:517–22. https://doi.org/10.3892/mco.2019.1913.

38. Senkus E, Gomez H, Dirix L, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019;177:549–59. https://doi.org/10.1007/s10549-019-05318-5.

39. Zhang C, Cui L, Zhang L, et al. Sexual activity and function assessment in middle-aged Chinese women using the female sexual function index. Menopause. 2017a;24:669–76. https://doi.org/10.1097/GME.0000000000000812.

40. Zhang P, Li CZ, Jiao GM, et al. Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2017b;43:1161–72. https://doi.org/10.1016/j.ejso.2016.11.011.

41. Zhang Y, Chen Y, Ma L. Depression and cardiovascular disease in elderly: Current understanding. J Clin Neurosci. 2018;47:1–5. https://doi.org/10.1016/j.jocn.2017.09.018.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.